Saturday, November 12, 2011

And Now Low-Salt Is BAD?

Low-salt diet increases heart attack risk, say Danish researchers

Study finds that reducing sodium intake leads to 2.5 percent jump in cholesterol levels and 7 percent increase in trigylcerides

Friday, November 11 2011, 1:34 PM


To salt or not to salt? For decades health experts have been warning people to put down the salt shaker to reduce their risks of heart attack and stroke. But a new study finds that while cutting back on salt does in fact lower blood pressure, it can also boost cholesterol levels.

Published Wednesday, Danish researchers report in the American Journal of Hypertension that reducing sodium consumption led to a one percent drop in blood pressure in people who had normal pressure readings, and a 3.5 percent drop in those with hypertension.

But at the same time, people who reduced their salt intake also saw a 2.5 percent jump in cholesterol levels and a 7 percent increase in trigylcerides, which can boost risks for heart disease and diabetes.

ESSENTIALS: SALT

Experts told health news site LiveScience that while the findings warrant further research, it's too soon to overturn the recommendations to keep salt levels low just yet. Too much sodium has been found to lead to high blood pressure, heart disease and strokes, yet most people are consuming more than three times the daily minimum requirement of 1,500 mg of sodium a day.

In general, being mindful of sodium in your diet can increase your intake of fresh vs. canned or processed foods, which can give your overall health a boost. The Mayo Clinic also advises to opt for low sodium foods and use fresh herbs to flavor meals. The American Heart Association recommends selecting unsalted nuts, and avoiding adding salt and canned vegetables in favor of homemade dishes.
AFP/Relaxnews

Another Wacky Diet Drug

My comments after the article

~~~

Experimental drug takes pounds off overweight monkeys

Success of Adipotide in lab tests could lead to breakthrough in fight against human obesity

Friday, November 11 2011, 1:23 PM

An experimental drug helped obese monkeys lose 11 percent of their extra weight in a month, a promising sign in the hunt for obesity drugs that could apply to humans, US researchers said.

The drug, known as Adipotide, works by attacking the blood supply of a certain kind of fat, known as white adipose tissue, that tends to accumulate under the skin and around the belly.

Most other obesity drugs focus on either reducing appetite, boosting metabolism or preventing the absorption of fat.

The research, led by the University of Texas MD Anderson Cancer Center, offers a potential new pathway for treatment and has also shown effects in mice who lost 30 percent of their body weight during treatment.
"Most drugs against obesity fail in transition between rodents and primates," said co-senior author Renata Pasqualini, whose study appears in the journal Science Translational Medicine.

DO THE MATH: WEIGHT LOSS TIP

"We're greatly encouraged to see substantial weight loss in a primate model of obesity that closely matches the human condition."

The monkeys in the study were spontaneously obese, meaning they overate of their own free will, avoided exercise and therefore had packed on extra pounds.

Their weight declined for the first three weeks of treatment, though a small uptick was seen in the fourth week. The average weight loss during that span of time was 11 percent of their body weight.

The drug designed by the MD Anderson group "binds to a protein on the surface of fat-supporting blood vessels," and contains a "synthetic peptide that triggers cell death," the findings said.

"Their blood supply gone, fat cells are reabsorbed and metabolized."

Clinical trials of the drug on obese men with prostate cancer are planned next, in which human subjects will get daily injections of the drug for 28 days.

"The question is, will their prostate cancer become better if we can reduce their body weight and the associated health risks?" asked co-author Wadih Arap, a professor in MD Anderson's David H. Koch Center for Applied Research of Genitourinary Cancers.

Another promising sign was that monkeys treated with the drug showed an improvement in their resistance to insulin, suggesting it may help ward off the development of type 2 diabetes.

However, it was seen to have some damaging effects to the kidneys, which could be lessened by administering the drug in smaller doses.

The journal noted that Arap, Pasqualini and some other researchers involved in the project own equity positions in two drug-development companies working on the research.

Those positions are "subjected to certain restrictions under institutional policy. MD Anderson manages and monitors the terms of these arrangements in accordance with its conflict-of-interest policy," it said.

Funding for the research came from grants from the National Institutes of Health, the National Cancer Institute and several other foundations.
AFP/Relaxnews
~~~~~
So, you take this injection which somehow kills off the blood supply to only a certain kind of cell, causing those particular cells to be killed off, giving you about a 10% weight loss in the first 3 weeks, BUT you start to regain by week four AND it starts to destroy your kidneys by that time, too?


And somebody thinks this is a GOOD idea??


Besides, is there anyone left on earth that doesn't know you can lose substantial amounts of weight in the first few weeks of any weight loss scam but it immediately starts to come right back on unless you take further steps, such as exercising more and eating even less?


I think I'll avoid this drug, TYVM.

I Miss Richard Simmons

 The voice, the hair, the outfits, that laugh - I miss every single thing about that glitzy, ditsy, outrageous person. Oh, yes, his workouts...